Under the terms of the partnership, the companies will work together in the production and marketing of certain APIs for use in the treatment of addiction, abuse prevention, cannabinoids for clinical indications and for the treatment of attention deficit hyperactivity disorder (ADHD). Noramco will be the … Read More
The post Strategic partnership formed to produce US DEA controlled substances appeared first on Dagga Magazine.